Williamson K, Robertson J F, Ellis I O, Elston C W, Nicholson R I, Blamey R W
City Hospital, Nottingham, UK.
Br J Surg. 1988 Jun;75(6):595-6. doi: 10.1002/bjs.1800750634.
In a phase I clinical trial Zoladex was used as first line hormonal therapy in premenopausal women with advanced breast cancer. Patients on progression of their disease underwent surgical oöphorectomy. The histology of ovaries from 23 women treated with Zoladex has been compared with the ovaries from 34 patients who, before the clinical trial of Zoladex, underwent surgical oöphorectomy as primary therapy. Both groups show similar follicular phase development. Only 13 per cent of the Zoladex group developed corpora lutea while 58 per cent showed evidence of luteinization in the primary oöphorectomy group (P less than 0.01). Non-neoplastic follicular cysts were seen more often in the ovaries of the Zoladex treated patients than in the primary oöphorectomy group (P less than 0.05). Zoladex appears to arrest not folliculogenesis but follicular maturation with inhibition of ovulation, the follicles subsequently undergoing atresia with follicular cyst formation.
在一项I期临床试验中，戈舍瑞林被用作绝经前晚期乳腺癌女性的一线激素治疗。疾病进展的患者接受了手术去势。将23例接受戈舍瑞林治疗的女性的卵巢组织学与34例在戈舍瑞林临床试验前接受手术去势作为主要治疗的患者的卵巢进行了比较。两组均显示出相似的卵泡期发育。戈舍瑞林组只有13%出现黄体，而在原发性去势组中58%有黄体化证据（P<0.01）。与原发性去势组相比，接受戈舍瑞林治疗患者的卵巢中更常出现非肿瘤性卵泡囊肿（P<0.05）。戈舍瑞林似乎不是阻止卵泡发生，而是抑制卵泡成熟并抑制排卵，随后卵泡闭锁并形成卵泡囊肿。
